Siga Technologies (SIGA)

Overall impact
C (59)

Commentary

Siga Technologies is an average overall performer. With a 'C' rating of 59.5 for overall impact (61st percentile compared to all companies), Siga Technologies ranks 417th out of 585 industry peers, behind Biogen, Ionis Pharmaceuticals, Gilead Sciences and 413 others, and ahead of Grifols, Jazz Pharmaceuticals, Bluebird Bio and 165 others. On top material causes for Siga Technologies's industry (Pharmaceuticals & Biotech), Siga Technologies performs well in Disease Eradication (96.4 score) and performs poorly in Decent, Safe Work Opportunities (39.5 score), Humane Treatment of Animals (0.0), Technology Innovation (33.1) and 1 other cause where it received a 'D' or 'F' score.
Impact
Cause SIGA
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
49
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ny, United States
Share classes
SIGA
Description
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company that focuses on the health security market in the United States. Its lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Material causes
Ethos considers the following causes material for Siga Technologies, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.